Waters Corp: Analytical Lab Instruments Market Dynamics
Former VP of Product Instrument Development at Waters Corporation
inpractise.com/articles/waters-corp-analytical-laboratory-instrument-market-dynamics
Waters Corp: Analytical Lab Instruments Market Dynamics(November 13, 2023)
Former VP of Product Instrument Development at Waters Corporation
The expert is a former Waters Corp executive with 19 years of experience in roles spanning product development, R&D, marketing, business development, and division management. As VP of Product Instrument Development, he was responsible for the liquid chromatography and mass spectrometry portfolio, leading dedicated teams across three continents.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
If I understand correctly, everyone is trained on all these instruments and software applications.
Yes, the switching costs include training staff. As Pharma has remodeled their supply chains and strived for efficiency, there's been a deskilling in the laboratory. The customers these companies were selling to 15 years ago were scientists, but now they're technicians. Retraining them can be a real challenge. This is why everyone's trying to make things simpler and easier to lower those switching costs.
This is a snippet of the transcript, sign up to read more.
What are your thoughts on the acquisition of Wyatt?
The argument is solid. They need a technology in that space that will assist them in research and development for characterization work. It's a detector that fits at the end of an LC. From a fit standpoint, it's excellent. The argument is perfectly logical. The challenging part is the valuation. The logic is clear, but I'm not sure about the financial aspect. They want it to be accretive within a year or two, and they must have an aggressive deal model to justify the valuation. That's the question.
This is a snippet of the transcript, sign up to read more.
Related Content
Waters Corp, Thermo Fisher, & Analytical Lab Instruments: A Customer's Perspective
R&D and Innovation Director at Quality Assistance
Illumina & The Evolution of Next-Generation Sequencing
Former Director at Illumina, Thermo Fisher Scientific and Pillar Biosciences
Danaher: Cytiva, HyClone, & Cell Culture Sales
Former Sales Specialist at Cytiva
Danaher & Sartorius: Promising Yield
Former Head of Sales at Sartorius Stedim Biotech
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.